NCT06491472

Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer

Efficacy and Safety of Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer：A Single-arm, Open-label, Phase II Clinical Study

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 36 (estimated)
• Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is an open-label, single-arm Phase II clinical study to evaluate the efficacy and safety of ivonescimab(AK112/SMT112) in combination with stereotactic body radiation therapy and chemotherapy in patients with pancreatic cancer

Conditions

• Pancreatic Cancer

Interventions

Type	Name	Description
DRUG	Ivonescimab	20mg/kg,IV,d1,Q3W
DRUG	Gemcitabine	1000mg/m2, IV, d1/8, Q3W
DRUG	Nab paclitaxel	125mg/m2, IV, d1/8, Q3W
RADIATION	SBRT	5Gy \*5 F

Timeline

• Start date: 2024-07-15
• Primary completion: 2026-07-15
• Completion: 2027-07-15
• First posted: 2024-07-09
• Last updated: 2024-07-09

Locations

1 site across 1 country: China